CLOs on the Move

Galderma Laboratories, L.P.

www.galderma.com

 
Galderma Laboratories, L.P. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fort Worth, TX. To find more information about Galderma Laboratories, L.P., please visit www.galderma.com
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion
  • www.galderma.com
  • 14501 North Fwy
    Fort Worth, TX USA 76177-3304
  • Phone: 817.961.5000

Executives

Name Title Contact Details
Devon Sharp
Associate General Counsel Profile
Grant Riedesel
Head of Legal, Corporate Development Profile
Tim Stow
Global Head of Ethics and Compliance Profile
Sean Griffin
Vice President of Regulatory Affairs Profile

Similar Companies

Zetta Medical Technologies

Zetta Medical Technologies is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Lake Zurich, IL. To find more information about Zetta Medical Technologies, please visit www.zettamed.com

CliniQAl Consult Corporation

CliniQAl Consult Corporation is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

St. Paul County Family and Community Support Services

St. Paul County Family and Community Support Services is a St Paul, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

NDRI National Disease Research Interchange

NDRI National Disease Research Interchange is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.